Tag: Peter Martin MD

REDLAMP 4: Circulating Tumor DNA & CT Monitoring for Untreated DLBCL – A Correlative Biomarker Study

First-line chemotherapy for diffuse large B-cell lymphoma is given with curative intent, but is not always effective. In this video, Dr. Peter Martin discusses the implications of a recently published study in Lancet Oncology, which aimed to discover whether a blood test capable of detecting circulating tumor DNA might predict treatment success or failure. In the future, blood tests may be added to, or even replace, current standard surveillance methods like CT scans or PET scans.

Previous #REDLAMP entries can be viewed on our Youtube channel.

We encourage you to follow the Lymphoma Program on Twitter, Youtube, and Facebook where we will highlight new videos are about research publications as they are released. We also welcome your feedback, suggestions and questions about this project. If you have other questions about our lymphoma program or clinical trials or would like to see one of our lymphoma specialists, please contact us at 646-962-2074.

Palbociclib and One Researcher’s Resolve

Palbociclib is a selective CDK4/6 inhibitor approved by the FDA for the treatment of patients with breast cancer. Currently it’s being tested in phase I trials for the treatment of patients with mantle cell lymphoma. The use of palbociclib as a cancer treatment was championed by Selina Chen-Kiang, PhD., professor of Pathology & Laboratory Medicine and Microbiology & Immunology, and a key collaborator with the Lymphoma Program. Palbociclib is currently considered one of the next big things in cancer treatment. But:

“..it’s old news for Selina Chen-Kiang, Ph.D…who has been a cheerleader for palbociclib for the past decade. In fact, her relentless effort helped resurrect the drug after it was shelved by an uninterested pharmaceutical company, and her initial findings inspired the clinical trials that paved the path for its accelerated approval.”    

“Chen-Kiang is renowned for her research in immunology and hematological malignancies. A molecular biologist by training, she first got swept into myeloma and lymphoma research while studying how antibody-secreting plasma cells were generated from B cells. Unlike solid tissue, normal immune cells can be isolated at different stages from mice and humans, making them the perfect model to study her primary passion: cell cycle control of immunity.”

Today Dr. Chen-Kiang’s dogged inquiry into the potential of palbociclib has the potential to help cancer patients. Her resolve exemplifies the bench portion of our bench to bedside approach at the Meyer Cancer Center. Palbociclib is currently undergoing phase I investigator-initiated trials, sponsored by the Cancer Therapy Evaluation Program at the National Cancer Institute at Weill Cornell Medical College. The principle investigator is Dr. Peter Martin. You can listen to him explain explain the benefits of this recently initiated trial:

New Clinical Trial: Open-label, Phase 2 Study of ACP-196 in Subjects with Mantle Cell Lymphoma

The Weill Cornell Lymphoma Program has recently opened a new clinical trial for men and women with mantle cell lymphoma. The study sponsor is Acerta Pharma BV, and the principal investigator at Weill Cornell is Peter Martin, M.D.. For more information about the study, please call Amelyn Rodgriguez, RN at (212) 746-1362 or e-mail Amelyn at amr2017@med.cornell.edu.

Key Eligibility

  • Men and women greater than or equal to 18 years of age
  • Patient has confirmed Mantle Cell Lymphoma (MCL)
  • The disease has relapsed after or been refractory to at least 1 prior therapy for MCL
  • Detailed eligibility reviewed when you contact the study team

Study Details

The purpose of this study is to determine the activity of ACP-196 in subjects with relapsed or refractory MCL as measured by response rate, duration of response, progression-free survival, and time-to-next treatment.

The design and conduct of this study is supported by an understanding of the natural history and current therapies for subjects with lymphoid cancers; knowledge of the activity and safety of the first-generation Btk inhibitor (eg, ibrutinib) in subjects with hematologic cancers; and the available nonclinical and clinical information regarding ACP-196.

This study is a multicenter, open-label, randomized, parallel group study. No placebo will be administered during this study. Twenty subjects, 10 refractory and 10 relapsed, will be enrolled and will take 100 mg of ACP-196 twice per day.

This clinical trial is a Phase 2, multicenter, open-label study. Subjects will be enrolled and will take 100 mg of ACP-196 twice per day (BID) continuously for approximately 14 months. Patients will continue on treatment as long as they are responding to therapy and not experiencing unacceptable side effects.